iScience (Nov 2023)
Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis
- Shobana Anpalakhan,
- Alessio Signori,
- Alessio Cortellini,
- Elena Verzoni,
- Raffaele Giusti,
- Giuseppe Aprile,
- Paola Ermacora,
- Annamaria Catino,
- Stefania Pipitone,
- Marilena Di Napoli,
- Vieri Scotti,
- Francesca Mazzoni,
- Pamela F. Guglielmini,
- Antonello Veccia,
- Marco Maruzzo,
- Giovanni Schinzari,
- Chiara Casadei,
- Francesco Grossi,
- Mimma Rizzo,
- Vincenzo Montesarchio,
- Francesco Verderame,
- Manlio Mencoboni,
- Fable Zustovich,
- Lucia Fratino,
- Caterina Accettura,
- Saverio Cinieri,
- Carlo Alberto Tondini,
- Andrea Camerini,
- Maria Chiara Banzi,
- Mariella Sorarù,
- Paolo Andrea Zucali,
- Francesca Vignani,
- Serena Ricciardi,
- Antonio Russo,
- Agnese Cosenza,
- Massimo Di Maio,
- Ugo De Giorgi,
- Sandro Pignata,
- Diana Giannarelli,
- Carmine Pinto,
- Sebastiano Buti,
- Giuseppe Fornarini,
- Sara Elena Rebuzzi,
- Pasquale Rescigno,
- Alfredo Addeo,
- Giuseppe L. Banna,
- Melissa Bersanelli
Affiliations
- Shobana Anpalakhan
- Portsmouth Hospitals University NHS Trust, Portsmouth, UK
- Alessio Signori
- University of Genoa, Genoa, Italy
- Alessio Cortellini
- Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy; Facility of Epidemiology & Biostatistics, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy
- Elena Verzoni
- SS.Oncologia Genitourinaria, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
- Raffaele Giusti
- Medical Oncology Unit, Azienda Ospedaliero-Universitaria Sant’Andrea, Roma, Italy
- Giuseppe Aprile
- Department of Oncology, San Bortolo General Hospital, Unità Locale Socio-Sanitaria (ULSS) 8 Berica-East District, Vicenza, Italy
- Paola Ermacora
- Department of Oncology, Presidio Ospedaliero Universitario Santa Maria della Misericordia, Azienda Sanitaria Universitaria Integrata Friuli Centrale, Udine, Italy
- Annamaria Catino
- Medical Thoracic Oncology Unit, IRCCS Istituto Tumori ''Giovanni Paolo II'', Bari, Italy
- Stefania Pipitone
- Medical Oncology Unit, University Hospital of Modena, Modena, Italy
- Marilena Di Napoli
- UC Oncologia Medica Uro-Ginecologica, Istituto Nazionale Tumori ''Fondazione G. Pascale'', IRCCS, Napoli, Italy
- Vieri Scotti
- Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy
- Francesca Mazzoni
- Medical Oncology Unit, Oncology Department, Careggi University Hospital, Firenze, Italy
- Pamela F. Guglielmini
- S.C. Oncologia, AO SS Antonio e Biagio e C. Arrigo, Alessandria, Italy
- Antonello Veccia
- Medical Oncology, Santa Chiara Hospital, Trento, Italy
- Marco Maruzzo
- Oncologia Medica 1, Istituto Oncologico Veneto IOV–IRCCS, Padova, Italy
- Giovanni Schinzari
- Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy
- Chiara Casadei
- Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy
- Francesco Grossi
- Medical Oncology Division, University of Insubria, ASST dei Sette Laghi, Varese, Italy
- Mimma Rizzo
- IRCCS San Matteo University Hospital Foundation, Pavia, Italy; Medical Oncology Unit, University Hospital - Polyclinic of Bari, Bari, Italy
- Vincenzo Montesarchio
- U.O.C. Oncologia, Azienda Ospedaliera Specialistica dei Colli, Ospedale Monaldi, Napoli, Italy
- Francesco Verderame
- Oncology Unit AO Azienda Ospedaliera Ospedali Riuniti ''Villa Sofia - Cervello'', Palermo, Italy
- Manlio Mencoboni
- Oncologia Medica, Ospedale Villa Scassi, Genova, Italy
- Fable Zustovich
- UOC Oncologia di Belluno, Dipartimento di Oncologia Clinica, AULSS 1 Dolomiti, Ospedale S.Martino, Belluno, Italy
- Lucia Fratino
- Medical Oncology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Pordenone, Italy
- Caterina Accettura
- Medical Oncology Unit, Ospedale Vito Fazzi, Lecce, Italy
- Saverio Cinieri
- Medical Oncology Division and Breast Unit, Senatore Antonio Perrino Hospital, ASL Brindisi, Brindisi, Italy
- Carlo Alberto Tondini
- Oncologia Medica, Ospedale Papa Giovanni XXIII, Bergamo, Italy
- Andrea Camerini
- Oncologia Medica, Ospedale della Versilia, Lido di Camaiore, Italy
- Maria Chiara Banzi
- Medical Oncology, Comprehensive Cancer Centre, AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
- Mariella Sorarù
- Medical Oncology, Camposampiero Hospital, Camposampiero (Padua), Italy
- Paolo Andrea Zucali
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; Department of Oncology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
- Francesca Vignani
- Department of Oncology, University of Turin, Turin, Italy; Medical Oncology, AO Ordine Mauriziano, Turin, Italy
- Serena Ricciardi
- Pulmonary Oncology Unit, San Camillo-Forlanini Hospital, Rome, Italy
- Antonio Russo
- Dipartimento di Discipline Chirurgiche, Oncologiche e Stomatologiche, Università degli Studi di Palermo, Palermo, Italy
- Agnese Cosenza
- Medical Oncology Unit, University Hospital of Parma, Parma, Italy
- Massimo Di Maio
- Department of Oncology, University of Turin, Turin, Italy; Medical Oncology, AO Ordine Mauriziano, Turin, Italy
- Ugo De Giorgi
- Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy; University Hospital Geneva, Geneva, Switzerland
- Sandro Pignata
- UC Oncologia Medica Uro-Ginecologica, Istituto Nazionale Tumori ''Fondazione G. Pascale'', IRCCS, Napoli, Italy; University Hospital Geneva, Geneva, Switzerland
- Diana Giannarelli
- Facility of Epidemiology & Biostatistics, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy
- Carmine Pinto
- Medical Oncology, Comprehensive Cancer Centre, AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy; University Hospital Geneva, Geneva, Switzerland
- Sebastiano Buti
- Medical Oncology Unit, University Hospital of Parma, Parma, Italy; Medicine and Surgery Department, University of Parma, Parma, Italy
- Giuseppe Fornarini
- Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
- Sara Elena Rebuzzi
- Medical Oncology Unit, Ospedale San Paolo, 17100 Savona, Italy
- Pasquale Rescigno
- Translational and Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK
- Alfredo Addeo
- University Hospital Geneva, Geneva, Switzerland; Corresponding author
- Giuseppe L. Banna
- Portsmouth Hospitals University NHS Trust, Portsmouth, UK; Faculty of Science and Health, School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK; Corresponding author
- Melissa Bersanelli
- Medical Oncology Unit, University Hospital of Parma, Parma, Italy; Federation of Italian Cooperative Oncology Groups (FICOG), Milan, Italy
- Journal volume & issue
-
Vol. 26,
no. 11
p. 107970
Abstract
Summary: The neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammatory index (SII) have been reported as prognosticators in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and melanoma. This analysis of the INVIDIa-2 study on influenza vaccination in patients with cancer treated with immune checkpoint inhibitors (ICIs) assessed NLR and SII on overall survival (OS) by literature-reported (LR), receiver operating characteristic curve (ROC)-derived (ROC) cutoffs or as continuous variable (CV). NLR and SII with ROC cutoffs of <3.4 (p < 0.001) and <831 (p < 0.001) were independent factors for OS in multivariate analysis. SII with LR, ROC, or CV significantly predicted OS in NSCLC (p = 0.002, p = 0.003, p = 0.003), RCC (p = 0.034, p = 0.014, p = 0.014), and melanoma (p = 0.038, p = 0.022, p = 0.019). NLR with LR and ROC cutoffs predicted OS in first line (p < 0.001 for both) and second line or beyond (p = 0.006 for both); likewise SII (p < 0.001; p = 0.002 and p < 0.001). NLR and SII are prognosticators in NSCLC, RCC, and melanoma treated with ICIs.
